Last updated 16 days ago

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

64 patients around the world
Available in Brazil, United States
The duration per participant will be up to 152 weeks.
Sanofi
1Research sites
64Patients around the world
This study is for people with
Esophagitis
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul
Recruiting
Av. Ipiranga, 6690 - 4º andar - Partenon, Porto Alegre - RS, 90610-001, Brazil
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy